Terns Pharmaceuticals (NASDAQ:TERN) Upgraded at Wall Street Zen

Terns Pharmaceuticals (NASDAQ:TERN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also commented on TERN. William Blair raised shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, November 3rd. Barclays increased their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th. UBS Group raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, JMP Securities set a $35.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.80.

Terns Pharmaceuticals Stock Performance

NASDAQ:TERN opened at $37.79 on Friday. The company has a market cap of $3.92 billion, a PE ratio of -36.69 and a beta of -0.28. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $48.26. The stock has a 50-day simple moving average of $38.73 and a 200 day simple moving average of $21.15.

Insider Activity

In other news, CEO Amy L. Burroughs sold 71,339 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the sale, the chief executive officer owned 138,976 shares in the company, valued at approximately $5,294,985.60. This trade represents a 33.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 141,243 shares of company stock worth $5,311,090 over the last three months. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. DLD Asset Management LP acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth $138,000. AlphaQuest LLC boosted its stake in shares of Terns Pharmaceuticals by 9,088,200.0% in the 3rd quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock valued at $683,000 after purchasing an additional 90,882 shares in the last quarter. Candriam S.C.A. lifted its stake in Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after purchasing an additional 214,266 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Terns Pharmaceuticals during the second quarter worth about $4,765,000. Finally, American Century Companies Inc. raised its holdings in Terns Pharmaceuticals by 14.0% in the 2nd quarter. American Century Companies Inc. now owns 129,668 shares of the company’s stock valued at $484,000 after buying an additional 15,911 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.